Daily Journal Staff Writer
Cooley LLP and Sullivan & Cromwell LLP represented a pair of antibiotic drugmakers in their acquisition by Massachusetts-based Cubist Pharmaceuticals Inc. for more than $800 million each in deals announced Tuesday.
The move is the latest in a gush of health care deals this year.
Tedizolid phosphate, the leading drug candidate of San Diego-based Trius Therapeutics Inc., is in stage th...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In